CRBP Stock Analysis: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$8.27
-0.36 (-4.17%)
▼
5d:
-5.27%
30d:
+3.25%
90d:
-50.95%
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $8.27, which is considered fair relative to its 30-day fair value range of $7.98 to $8.81.
Technical Outlook: Technically, CRBP is in a downtrend. The price is currently testing key support at $8.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $42.33 (+411.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRBP is in a downtrend. The price is currently testing key support at $8.05. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $42.33 (+411.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$7.98 -
$8.81
Company Quality Score
51/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
55.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 411.9% below Wall St target ($42.33)
- CAUTION: 5-day price weakness (-5.3%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$7.98 -
$8.81
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$2.30
(27.8%)
Support & Resistance Levels
Support Level
$8.05
Resistance Level
$9.57
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$42.33
(+411.9%)
Revenue Growth (YoY)
-100.0%
Last updated: February 02, 2026 8:42 AM ET
Data refreshes hourly during market hours. Next update: 9:42 AM
Data refreshes hourly during market hours. Next update: 9:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Anne Altmeyer
SELL
1060 shares
2025-10-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
